These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 27075078)

  • 41. Immunotherapy of Melanoma.
    Bender C; Hassel JC; Enk A
    Oncol Res Treat; 2016; 39(6):369-76. PubMed ID: 27259558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytotoxic T-lymphocyte-associated antigen-4.
    Salama AK; Hodi FS
    Clin Cancer Res; 2011 Jul; 17(14):4622-8. PubMed ID: 21467163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The conquest of melanoma by immunotherapy.
    Lejeune FJ
    Melanoma Res; 2015 Oct; 25(5):373-5. PubMed ID: 26173006
    [No Abstract]   [Full Text] [Related]  

  • 44. Adult ALL: where are we and where are we going?
    Larson RA
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):342-4. PubMed ID: 16163203
    [No Abstract]   [Full Text] [Related]  

  • 45. Monoclonal antibodies: versatile platforms for cancer immunotherapy.
    Weiner LM; Surana R; Wang S
    Nat Rev Immunol; 2010 May; 10(5):317-27. PubMed ID: 20414205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
    Lotem M; Merims S; Frank S; Ospovat I; Peretz T
    Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nobel goes to immune checkpoint-Innovative cancer treatment by immunotherapy.
    Li J; Dong C
    Sci China Life Sci; 2018 Nov; 61(11):1445-1450. PubMed ID: 30377902
    [No Abstract]   [Full Text] [Related]  

  • 48. Drug development: Releasing the brakes.
    Weintraub K
    Nature; 2013 Dec; 504(7480):S6-8. PubMed ID: 24352363
    [No Abstract]   [Full Text] [Related]  

  • 49. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Checkpoint inhibitors in breast cancer: hype or promise?
    McArthur HL
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
    [No Abstract]   [Full Text] [Related]  

  • 51. [Cancer immunotherapy: recent breakthroughs and perspectives].
    Tartour E; Sandoval F; Bonnefoy JY; Fridman WH
    Med Sci (Paris); 2011 Oct; 27(10):833-41. PubMed ID: 22027420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [21 years in the treatment of acute lymphoblastic leukemias in children (1967-1987)].
    Ortega JJ; Javier G; Olivé T; Montagut JM
    Sangre (Barc); 1988 Oct; 33(5):372-82. PubMed ID: 3073534
    [No Abstract]   [Full Text] [Related]  

  • 53. Releasing the Brakes on Cancer Immunotherapy.
    Ribas A
    N Engl J Med; 2015 Oct; 373(16):1490-2. PubMed ID: 26348216
    [No Abstract]   [Full Text] [Related]  

  • 54. [Monoclonal antibodies and cancer].
    López González JS; Selman Lama M
    Salud Publica Mex; 1985; 27(3):213-34. PubMed ID: 2996157
    [No Abstract]   [Full Text] [Related]  

  • 55. Whole tumor cell vaccines for glioma immunotherapy.
    Field CS; Hermans IF; Hunn MK
    Immunotherapy; 2016; 8(4):387-9. PubMed ID: 26973119
    [No Abstract]   [Full Text] [Related]  

  • 56. The immune checkpoint inhibitors: where are we now?
    Webster RM
    Nat Rev Drug Discov; 2014 Dec; 13(12):883-4. PubMed ID: 25345674
    [No Abstract]   [Full Text] [Related]  

  • 57. Combination immunotherapy approaches.
    Drake CG
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii41-6. PubMed ID: 22918927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
    Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
    Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug development: a chance of survival.
    Hoag H
    Nature; 2014 Nov; 515(7527):S118-20. PubMed ID: 25407709
    [No Abstract]   [Full Text] [Related]  

  • 60. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y; Choudhury A; Kiessling R
    Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.